Back to Search Start Over

Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX

Authors :
Shitara, Kohei
Matsuo, Keitaro
Takahari, Daisuke
Yokota, Tomoya
Inaba, Yoshitaka
Yamaura, Hidekazu
Sato, Yozo
Najima, Mina
Ura, Takashi
Muro, Kei
Source :
European Journal of Cancer. Jul2009, Vol. 45 Issue 10, p1757-1763. 7p.
Publication Year :
2009

Abstract

Abstract: We retrospectively analysed 153 patients with metastatic colorectal cancer who received FOLFOX with or without bevacizumab as first-line chemotherapy. Several background characteristics and chemotherapy features (grade of neutropaenia, use of bevacizumab or irinotecan, re-introduction of FOLFOX, and tumour progression) as time-varying covariates were analysed as potential prognostic factors. Of the 153 patients, mild neutropaenia (grade 1–2) occurred in 60 patients (39%) and severe neutropaenia (grade 3–4) occurred in 46 patients (30%). The other 47 patients (31%) did not experience neutropaenia. According to a multivariate Cox model with time-varying covariates, hazard ratios (HRs) of death were 0.55 (95% confidence interval (CI), 0.31–0.98; P =0.044) for patients with mild neutropaenia and 0.35 (95% CI, 0.18–0.66; P =0.002) for those with severe neutropaenia. Both mild and severe neutropaenia during chemotherapy are associated with improved survival in patients with MCRC. Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy. [Copyright &y& Elsevier]

Details

Language :
English
ISSN :
09598049
Volume :
45
Issue :
10
Database :
Academic Search Index
Journal :
European Journal of Cancer
Publication Type :
Academic Journal
Accession number :
42104107
Full Text :
https://doi.org/10.1016/j.ejca.2009.01.019